

Special 510(k): Device Modification: Lp(a) SPQ™ III Antibody Reagent Set

10 510(k) Summary

K994110

December 3, 1999

Submitted By: Judith J. Smith  
DiaSorin, Inc.  
Quarry Park Place, Suite 100  
9175 Guilford Road  
Columbia, MD 21046

Name Of Device:  
Trade Name: Lipoprotein(a) SPQ™ III Antibody Reagent Set

Common Name: Lipoprotein(a) Immunological Test Kit

Classification Name: Lipoprotein(a), antigen, antiserum, control (82DFC)

Device Classification Class II

Predicate Device: SPQ™ III Antibody Reagent Set for Lipoprotein(a)

Device Description: Lipoprotein(a) Immunological Test Kit

Intended Use: FOR IN VITRO DIAGNOSTIC USE.  
The SPQ™ Antibody Reagent Set for Lp(a) is designed for the quantitative determination of human lipoprotein(a) in mg/dL in human serum by immunoprecipitin analysis using a turbidimetric clinical analyzer. The measurement of Lp(a) is indicated for use in conjunction with clinical evaluation, patient risk assessment and other lipoprotein tests to evaluate disorders of lipid metabolism and to assess coronary heart disease (CHD) in male Caucasian populations.

Technological Comparison: The modified device has the same technological basis as the predicate device.

Labeling Comparison: The labeling of the modified device is substantially equivalent to that of the predicate device. Changes in the labeling and package insert directly reflect the device modification (the additional instrument application for the Hitachi 911).

**Bench Testing**

With Clinical Samples: Bench testing with clinical samples demonstrated that the performance characteristics of the modified device were substantially equivalent to those of the predicate device.

**Conclusions from  
Testing:**

The modified device is substantially equivalent to the predicate device.



DEPARTMENT OF HEALTH & HUMAN SERVICES

DEC 21 1999

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Ms. Judith J. Smith  
Vice President,  
Worldwide Regulatory Affairs and Quality Systems  
Diasorin/American Standard Companies  
9175 Guilford Road, Suite 100  
Quarry Park Place  
Columbia, Maryland 21046

Re: K994110  
Trade Name: SPQ™ III Test System Antibody Reagent Set for Lp(a)  
Regulatory Class: II  
Product Code: DFC  
Dated: December 3, 1999  
Received: December 6, 1999

Dear Ms. Smith:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895.

A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.


Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.  
Director  
Division of Clinical  
Laboratory Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

#### 4 Intended Use/Indications For Use

510(k) Number: K994110

Device Name: SPQ™ III Test System Antibody Reagent Set for Lp(a)

Intended Use/Indications For Use:

**FOR IN VITRO DIAGNOSTIC USE.**

The SPQ™ Antibody Reagent Set for Lp(a) is designed for the quantitative determination of human lipoprotein(a) in mg/dL in human serum by immunoprecipitin analysis using a turbidimetric clinical analyzer. The measurement of Lp(a) is indicated for use in conjunction with clinical evaluation, patient risk assessment and other lipoprotein tests to evaluate disorders of lipid metabolism and to assess coronary heart disease (CHD) in male Caucasian populations.

Jan Cooper  
(Division Sign-Off)  
Division of Clinical Laboratory Devices  
510(k) Number K994110

---

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF  
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓ OR Over-The-Counter Use \_\_\_\_\_ (Per 21 CFR 801.109)